Usefulness of portal vein pressure for predicting the effects of tolvaptan in cirrhotic patients

Table 2 Comparison of demographic and clinical characteristics at baseline between responders and non-responders

Characteristics	Responder (n = 17)	Non-responder (n = 23)	P value
Age (yr)	66 (45-80)	61 (40-82)	0.8137
Body weight (kg)	62.3 (44.8-88.5)	61.7 (50.3-79.2)	0.7857
Liver disease etiology (Hepatitis B/Hepatitis C/Alcohol/PBC/PSC/NASH)	3/5/5/2/1/1	0/10/10/1/0/2	-
Child-Pugh classification (A-B/C)	9/8	13/10	1.000
Total bilirubin (mg/dL)	0.8 (0.4-11.4)	1.3 (0.5-26.2)	0.332
Serum albumin (g/dL)	2.5 (1.9-3.5)	2.6 (1.6-3.7)	0.733
Serum creatinine (mg/dL)	0.91 (0.62-1.83)	1.1 (0.45-6.45)	0.480
Serum eGFR (mL/min/1.73 m2)	62 (24-85)	51 (8-112)	0.290
Serum sodium (mEq/L)	137.5 (125-146)	140 (124-144)	0.855
Serum hyaluronic acid (ng/mL)	335 (181-2843)	567.9 (122-6984)	0.017
BUN (mg/dL)	18.1 (8.1-81)	20.9 (10.1-81.8)	0.211
Urine osmolality (mOsm/L)	418 (257-700)	361.5 (254-954)	0.293
Hepatic venous pressure gradient (mmH2O)1	170 (105-580)	255 (150-350)	0.045
Hepatocellular carcinoma (with/without)	6/11	6/17	0.729
Esophageal varix (with/without)	10/7	15/8	0.518

¹Hepatic venous pressure gradient was measured in 24 patients. Categorical variables are given as number. Continuous variables are given as median (range). BUN: Blood urea nitrogen; PBC: Pimary biliary cirrhosis; PSC: Primary sclerosing cholangitis; NASH: Nonalcoholic steatohepatitis.